Guerrero C, et al. - Given that patients with acute coronary syndromes (ACS) and anemia are commonly treated with clopidogrel in routine clinical practice, the researchers examined the prevalence of anemia and characteristics and outcomes of these patients according to anemia status. For this investigation, consecutive patients with ACS from 11 centers were involved. The data presented in this work showed a not negligible proportion of patients treated with ticagrelor or prasugrel met criteria for anemia. They reported that anemia was an independent predictor of mortality. Findings revealed that patients with anemia had an acceptable rate of bleeding in spite of their higher bleeding risk profile.